Introduction
O 6 -alkylguanine-DNA alkyltransferase (AGT) repairs DNA damage from alkylating agents by transferring the alkyl group and other adducts from the O 6 -position of guanine in DNA to an internal cysteine residue in the AGT protein and rendering the protein inactive [1] . In tumors, AGT confers resistance to alkylating agents such as temozolomide and the chloroethylnitrosoureas. O 6 -benzylguanine (O 6 -BG) depletes AGT by acting as a substrate and thereby enhances the activity of agents that alkylate the O 6 -position of guanine [2] . Continuous infusion of O 6 -BG for up to 48 h in patients depletes tumor AGT activity [3] . However, combining O 6 -BG with carmustine or temozolomide in adults and children with solid tumors enhanced the toxicity of the chemotherapy, requiring a reduction in the dose to less than half the standard dose [3] [4] [5] [6] .
O 4 -benzylfolic acid (O 4 BF) ( Fig. 1 ) is a folate analogue and an inhibitor of AGT that is more water soluble and approximately 30-fold more potent than O 6 BG [7, 8] . Cellular uptake of O 4 BF appears to be mediated by the alpha-folate receptor [7] , which has limited expression in normal tissues but is over-expressed in many primary and metastatic cancers, such as ovarian, uterine, endometrial, cervical and pancreatic carcinomas, ependymal brain tumors, mesothelioma and testicular choriocarcinoma, and to a lesser extent in breast, colon and renal cancers [9, 10] . Selective uptake of O 4 BF into tumor cells may lessen the severity of systemic toxicity that occurred when O 6 BG was combined with alkylating agents and allow for administration of higher doses of conventional chemotherapy in conjunction with O 4 BF. The alkylating agents with which O 4 BF is likely to be combined are primarily used to treat brain tumors; therefore, the penetration of O 4 BF into the CNS may impact on its ability to enhance the anti-tumor effects of the alkylating agents. We studied the toxicity and the plasma and cerebral spinal fluid (CSF) pharmacokinetics of O 4 BF in a non-human primate model (NHP). [7] . Aldehyde oxidase (AO) was isolated as previously described from rabbit livers [11, 12] .
Materials and methods

Chemicals
Animals
Adult male rhesus monkeys (Macaca mulatta) weighing 8.1-14.8 kg with an indwelling Ommaya reservoir attached to a catheter in the fourth ventricle were utilized in this study (3 animals, 8 experiments) [13] . Animals were group housed in accordance with the Guide for the Care and Use of Laboratory Animals [14] . This study was approved by the NCI Animal Care and Use Committee.
Drug administration and PK sampling O 4 BF (10-50 mg/kg) was diluted in normal saline to a final volume of 30 ml and infused intravenously (IV) over 30 min. Blood samples were drawn from a central or peripheral venous catheter contralateral to the site of drug infusion. CSF samples were drawn from the Ommaya reservoir. Paired CSF and blood samples were drawn prior to infusion, at end of infusion (EOI) and 30 min, 1, 2, 4, 6, 8, 10, 24, 48, and 72 h after infusion. Additional blood samples were drawn 5 and 15 min after the start of the infusion and 5 and 15 min after EOI. Blood samples were immediately centrifuged and plasma was separated. Plasma and CSF were stored at -70°C until assayed.
Sample processing, HPLC assay development and validation
The internal standard O 4 -propylfolic acid (40 mcl of a 250 mM stock solution) was added to 0.5 ml of plasma, which was then deproteinated with 1 ml of acetonitrile (ACN). Samples were vortexed, placed in a shaker for 10 min and centrifuged at 10,000 rpm for 10 min. Supernatant was collected, evaporated in a 37°C water bath under a stream of nitrogen and reconstituted in 200 mcl of mobile phase. Analyte concentrations were measured by HPLC (Alliance 2695, Waters, Milford, CT) using a Waters Symmetry C8 (5 micron, 3.9 9 150 mm) column and Phenomenex security guard column (Torrance, CA) with a photo diode array (PDA) detector (Waters Model 996, Waters, Milford, CT). Mobile phase was 72% 0.01 M sodium phosphate (pH 6.9)/28% methanol at a flow rate of 1 ml/min. Injection volume was 50 mcl. Empower Pro version 5.0 software was used for data analysis. The HPLC/ PDA assay was linear from 0.2-20 mcM in plasma. The inter-and intraday variability (CV%) was \10%.
Analyte concentrations in CSF samples were undetectable using the HPLC/PDA method; therefore, an HPLC/ MS/MS assay was developed and validated for CSF using a MDS Sciex API 5000 triple quadrupole mass spectrometer (Applied Biosystems, Foster City, CA) with Shimadzu HPLC system (Columbia, MD). Chromatographic separation was performed with a Phenomenex Luna C8, 3 micron, 2 9 50 mm column (Torrance, CA), autosampler temperature 4°C and column heater 40°C. Mobile phase consisted of 0.1% formic acid and acetonitrile (80:20) at a flow rate of 0.25 ml/min. Source and compound-dependent MS parameters were optimal under the following conditions: collision gas 6 psi, curtain gas 20 psi and ion source 1 20 psi; ion spray voltage 5000 V, declustering potential 61 V, entrance potential 10 V and collision energy 25 V; ion source temperature 500°C. CSF injection volume was 20 mcl. Quantification was performed using multiple reaction monitoring (MRM), and data analysis was performed with Analyst Ò software version 1.4.2. The HPLC/ MS/MS assay for CSF was linear from 0.1 to 100 nM. The inter-and intraday variability (CV%) was B10% .
Plasma and aqueous assays were validated using FDA assay validation guidelines. BF was incubated with aldehyde oxidase (AO) for 30 min at room temperature. Protein was precipitated from solution with 1 ml ACN, centrifuged and resulting supernatant was analyzed by HPLC/PDA and mass spectrometry. Meteor (LHASA Limited, Leeds, UK) was used to predict possible metabolite structures.
The ability of the metabolite to inactivate purified AGT was assessed as previously described [15] . Briefly, purified hAGT protein (20 ng) was incubated with a range of concentrations of O 4 BF, and the metabolite formed by incubation of O 4 BF with AO in 0.5 ml of 50 mM Tris-HCl, pH 7.6, 0.1 mM EDTA, 5 mM dithiothreitol and 50 mg hemocyanin at 37°C for 30 min. The residual AGT activity was determined by incubation with 
Pharmacokinetics
The area under the curve (AUC) for O 4 BF and its metabolite in plasma and CSF was calculated using the linear trapezoidal method. Metabolite concentrations were reported as O 4 BF-equivalents. The half-life (T ) for both compounds was calculated by dividing 0.693 by the slope of the terminal elimination phase of the plasma and CSF curves.
The CSF penetration of O 4 BF and metabolite was calculated from the AUC CSF :AUC plasma ratio.
Results
Metabolite identification and evaluation
The chromatograms from plasma showed a new peak that eluted after O 4 BF. This peak was not present in the preinfusion or 5-min sample (Fig. 2a) but was observed 30 min after the end of infusion (EOI) (Fig. 2b) and increased over time (Fig. 2c) . UV spectra of O 4 BF (Fig. 3a) and this putative metabolite (Fig. 3b) are shown in Fig. 3 . The UV and mass spectra of metabolite formed in vitro by incubation of O 4 BF with AO ( Fig. 3c ) and the metabolite peak in plasma (Fig. 3b) O 4 BF and metabolite were measurable in the CSF. However, CSF drug exposure of O 4 BF and its metabolite was \1% of plasma drug exposure (Table 1) . At the 50 mg/kg dose level, the C max in CSF for O 4 BF was less than 0.09 mcM and for the metabolite the C max ranged from 0.02 to 0.04 mcM (O 4 BF equivalents). 
Discussion
AGT plays an important role in the mechanism of tumor resistance to agents, such as carmustine and temozolomide that produce their cytotoxic effect by alkylating the O 6 -position of guanine [16] . O 6 -benzylguanine (O 6 BG) is an AGT inhibitor that modulates resistance to these alkylating agents in preclinical models, and it has been tested clinically in combination with carmustine and temozolomide [5, 6] . However, combining O 6 BG with these alkylating agents also enhanced their toxicity and limited the dose of standard chemotherapy that can be safely administered. O 4 BF is a potent AGT inhibitor that was reported to have greater tumor selectivity because its uptake into cells was thought to be dependent on the alpha-folate receptor, which is more highly expressed in tumor cells than in normal tissues. Subsequent studies failed to confirm the proposed selective uptake of this modulating agent, which enhanced the myelotoxicity of carmustine in the CFU-GM clonogenic assay using human bone marrow cells [8, 17] .
We studied the clinical pharmacology of O 4 BF in nonhuman primates. The pharmacokinetics of O 4 BF were characterized by a short half-life and rapid conversion to a metabolite with a substantially longer half-life and greater exposure than the parent compound. The metabolite, which is presumed to be 7-OH-O 4 BF, is an equipotent inhibitor of AGT.
The CSF penetration of O 4 BF and its metabolite is \1% relative to plasma drug exposure. In comparison, O 6-BG has a CSF penetration of 4.3 (±0.6)% and its primary metabolite, O6-benzy-8-oxoguanine, has a CSF penetration of 36 (±11)% [17] . The ED 50 for AGT inhibition by O 4 BF is approximately 0.04 mcM, and the C max of O 4 BF in the CSF at doses above 40 mg/kg exceeds this level. However, the recently reported lack of receptor specificity [18] in conjunction with this pharmacokinetic data suggesting saturable elimination of both O 4 BF and its metabolite and GI toxicity and myelosuppression seen in one non-human primate treated with 50 mg/kg may limit dose escalation and future clinical development of this agent. BF; for the metabolite, the AUC is calculated is to the last measured time point and CSF penetration for the metabolite is the ratio of the AUC to the same time point in CSF and plasma b Measured to 10 h
